|Application ||WB, IHC-P|
|Calculated MW||16533 Da|
|Purification||Antiserum to human CDKN2A was raised by repeated immunisation of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography.|
|Immunogen||A 19 amino acid peptide located near the amino terminus of human CDKN2A.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A, CDKN2A, CDKN2, MTS1|
|Target/Specificity||ABD11056 recognises human cyclin-dependent kinase inhibitor 2A (CDKN2A), a 16kDa protein belonging to the CDKN2 cyclin dependent kinase inhibitor family. CDKN2A acts as a negative regulator of cell proliferation by interacting strongly with CDK4 and CDK6, thus inhibiting their ability to interact with cyclin D and to phosphorylate the retinoblastoma protein. CDKN2A is an important tumour suppressor and defects in its production results in tumour formation in a wide range of tissues, including cutaneous malignant melanoma and Li-Fraumeni syndrome.|
|Preservative & Stabilisers||0.02% Sodium Azide (NaN3)|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-CDKN2A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Stone, S. et al. (1995) Complex structure and regulation of the P16 (MTS1) locus.Cancer Res. 1995; 55:2988-2994. 2. Kamb, A. et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8:22-26.3. Kratzke, R.A. et al. (1995) Immunohistochemical analysis of the p16(INK4) cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Nat. Cancer Inst. 87:1870-18754. Stott.,F.J. et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17:5001-5014.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.